Education
About Us
Working with TipRanks
Follow Us
Genelux Corp. (GNLX)
NASDAQ:GNLX
GNLX Stock Chart & Stats
$2.49
-$0.06(-2.24%)
At close: 4:00 PM EST
$2.49
-$0.06(-2.24%)
Day’s Range― - ―
52-Week Range$1.99 - $8.54
Previous CloseN/A
Volume23.79K
Average Volume (3M)156.94K
Market Cap
$111.35M
Enterprise Value$95.11M
Total Cash (Recent Filing)$20.91M
Total Debt (Recent Filing)$1.62M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Apr 06, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding44,718,437
10 Day Avg. Volume178,540
30 Day Avg. Volume156,945
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)2.82
Price to Sales (P/S)9277.96
P/FCF Ratio-3.43
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-665.12
Enterprise Value/Ebitda-3.02
Forecast
1Y Price Target
$22.33Price Target Upside796.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Intravenous Administration De‑riskingInterim systemic administration data show acceptable safety and measurable tumor reductions, which could de‑risk intravenous delivery of Olvi‑Vec and broaden its application across multiple solid tumor types.
Mechanism-driven Resensitization To ChemotherapyOlvi‑Vec's multimodal action, including stromal breakdown and STAT1‑linked resensitization, could restore sensitivity to platinum chemotherapy and drive durable benefits in resistant tumors.
Registrational Progress In Ovarian CancerPositive prior Phase 2 results support the pivotal Phase 3 study in platinum‑resistant ovarian cancer, strengthening the likelihood that consistent outcomes could lead to a registrational pathway.
Bears Say
Cash Runway And Financing RiskA reported operating loss and a modest cash position create pressure to secure additional funding before late‑stage milestones, which could lead to dilution or program delays if capital is not obtained.
Prior Therapy May Limit EfficacyPatient populations who have already progressed on checkpoint inhibitors may show lower responses to Olvi‑Vec combinations, potentially constraining overall trial outcomes in those cohorts.
Small Sample Sizes And Limited Follow‑upVery small patient cohorts and short follow‑up in interim analyses increase statistical uncertainty and make it unclear whether early efficacy and safety signals will hold in larger studies.
Genelux Corp. News
GNLX FAQ
What was Genelux Corp.’s price range in the past 12 months?
Genelux Corp. lowest stock price was $1.99 and its highest was $8.54 in the past 12 months.
What is Genelux Corp.’s market cap?
Genelux Corp.’s market cap is $111.35M.
When is Genelux Corp.’s upcoming earnings report date?
Genelux Corp.’s upcoming earnings report date is Apr 06, 2026 which is in 50 days.
How were Genelux Corp.’s earnings last quarter?
Genelux Corp. released its earnings results on Nov 05, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.213 by $0.003.
Is Genelux Corp. overvalued?
According to Wall Street analysts Genelux Corp.’s price is currently Undervalued.
Does Genelux Corp. pay dividends?
Genelux Corp. does not currently pay dividends.
What is Genelux Corp.’s EPS estimate?
Genelux Corp.’s EPS estimate is -0.22.
How many shares outstanding does Genelux Corp. have?
Genelux Corp. has 44,718,437 shares outstanding.
What happened to Genelux Corp.’s price movement after its last earnings report?
Genelux Corp. reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.213. Following the earnings report the stock price went down -32.398%.
Which hedge fund is a major shareholder of Genelux Corp.?
Currently, no hedge funds are holding shares in GNLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genelux Corp. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.33 (796.79% Upside)
$22.33 (796.79% Upside)
Hedge Fund Trend
Decreased
By 631.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $39.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.5%
Last 30 Days ▼ 8.3%
Last 30 Days ▼ 8.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
136.72%
12-Months-Change
Fundamentals
Return on Equity
-98.72%
Trailing 12-Months
Asset Growth
-28.62%
Trailing 12-Months
Company Description
Genelux Corp.
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
GNLX Stock 12 Month Forecast
Average Price Target
$22.33
▲(796.79% Upside)
Technical Analysis
Coherus Biosciences
―
Fate Therapeutics
―
Tonix Pharma
―
Corbus Pharmaceuticals
―
Forte Biosciences
―
Ownership Overview
3.72% Insiders
3.57% Mutual Funds
4.44% Other Institutional Investors
85.16% Public Companies and
Individual Investors